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 CURRENTOPINION Quasi-experiments to establish causal effects of
HIV care and treatment and to improve the
cascade of care
Jacob Bor a,b, Pascal Geldsetzerc, Atheendar Venkataramanid, and
Till Ba¨rnighausenc,e
Purpose of review
Randomized, population-representative trials of clinical interventions are rare. Quasi-experiments have been
used successfully to generate causal evidence on the cascade of HIV care in a broad range of real-world
settings.
Recent findings
Quasi-experiments exploit exogenous, or quasi-random, variation occurring naturally in the world or
because of an administrative rule or policy change to estimate causal effects. Well designed quasi-
experiments have greater internal validity than typical observational research designs. At the same time,
quasi-experiments may also have potential for greater external validity than experiments and can be
implemented when randomized clinical trials are infeasible or unethical. Quasi-experimental studies have
established the causal effects of HIV testing and initiation of antiretroviral therapy on health, economic
outcomes and sexual behaviors, as well as indirect effects on other community members. Recent quasi-
experiments have evaluated specific interventions to improve patient performance in the cascade of care,
providing causal evidence to optimize clinical management of HIV.
Summary
Quasi-experiments have generated important data on the real-world impacts of HIV testing and treatment
and on interventions to improve the cascade of care. With the growth in large-scale clinical and
administrative data, quasi-experiments enable rigorous evaluation of policies implemented in real-world
settings.
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INTRODUCTION
The second decade of mass HIV treatment provision
has brought with it new hopes and challenges. On
the one hand, the large potential for reduced trans-
mission with early ART has led to optimism about
further expansions of HIV testing and treatment. On
the other hand, despite the widespread availability
of antiretroviral therapy (ART) and its efficacy, HIV
is still the leading cause of death in southern Africa
[1] and losses along the ‘cascade’ fromHIV testing to
initiating and sustaining ART remain high [2]. Con-
sequentially, there is strong interest in improving
the effectiveness and sustainability of interventions
through ‘implementation science’ research [3]. For-
tunately, we have at our disposal a decade of history
to learn from. Although such an approach would
have been infeasible during the initial ‘emergency’
phase of ART scale-up, we nowhave the capability to
look back and learn from existing experiences of
programmes, policies and interventions imple-
mented in real-world settings and at scale. In doing
so, researchers have an important tool at their dis-
posal, which provides powerful opportunities to
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REVIEW
grow the evidence base on the real-world effective-
ness of interventions along the HIV treatment cas-
cade: quasi-experiments.
In this article, we define quasi-experiments and
characterize specific study designs as examples of
the approach. We define the term narrowly, noting
that a range of study designs sometimes included
under the banner of quasi-experiments would not
meet the criteria we set out. Second, we describe the
benefits and limitations of quasi-experiments vis-a`-
vis the traditional stalwarts in empirical clinical and
epidemiological research: the randomized clinical
trial and the nonexperimental observational study.
(We note the importance of modeling and projec-
tion studies to inform policy decision-making, but
limit the discussion here to empirical studies of
causal effects.) Third, we review a recent wave of
studies that have used quasi-experimental designs
either to evaluate components of the HIV cascade of
care or to evaluate interventions to improve patient
progression through the cascade of care. In our
review, we draw out specific aspects of these studies
that highlight the strengths and capabilities of
quasi-experimental designs.
We note that a substantial portion of this liter-
ature comes from economics, and not all of these
studies are indexed in PubMed. (Economics publish-
ing timelines aremuch longer than in public health/
medicine, and research results are often available as
working papers or conference papers long before
they appear in publication.) All studies that we
review that were not included in PubMed are freely
available online and were accessed via Google
Scholar.
QUASI-EXPERIMENTS: A DEFINITION
Quasi-experiments are studies in which a treatment
or exposure is assigned by exogenous (or quasi-ran-
dom) variation occurring naturally in the world, or
resulting from an administrative rule, or policy
change, or intervention [4,5]. Exogeneity implies
that treatment assignment is not influenced by
factors associated with the outcome of interest
(i.e. confounders). In randomized-controlled trials,
exogeneity is achieved through the investigator’s
randomization of subjects to different exposures.
Although quasi-experiments are typically observa-
tional studies – studies in which exposure status is
not assigned by the investigator – quasi-exper-
iments have more similarities to randomized
clinical trials than to nonexperimental observatio-
nal studies in their approach to causal inference.
Nonexperimental study designs, such as multiple
regression, matching, reweighting, and stratifica-
tion adjust for measured confounders and rely for
causal inference on the ubiquitous but (often)
strong assumption that there are no unobserved
confounders. In contrast, and similar to randomized
trials, quasi-experiments identify off of exogenous
variation in treatment assignment that is plausibly
independent of unobserved confounders.
Several study designs fit this definition of a
quasi-experiment [6,7]: regression discontinuity
designs can be implemented when an exposure is
assigned by a threshold rule on a continuous pre-
treatment covariate (e.g. a clinical risk score),
exploiting the similarity of subjects just above and
below the threshold [8,9,10
&&
]. Interrupted time
series designs, a subset of regression discontinuity,
identify causal effects of rapid temporal changes in
exposure status within the same group of study
subjects. Difference-in-differences designs can be
used to identify the causal effect of a plausibly
exogenous change in exposure across differentially
exposed groups, for example a policy change or
environmental exposure that affected some regions
but not others [4]. More generally, exogenous vari-
ation in an exposure may be identified whenever
there is a valid instrumental variable – a variable
that is correlated with the exposure, but not inde-
pendently related to the outcome [11,12]. In fact,
instrumental variable methods can be used across
the full range of quasi-experimental designs to
obtain the causal effect of treatment itself within
the subpopulation induced to take up treatment –
rather than the intent-to-treat effect of treatment
KEY POINTS
 Quasi-experiments exploit exogenous, or quasi-random,
variation occurring naturally in the world or because of
an administrative rule or policy change to estimate
causal effects.
 Some quasi-experimental designs – the regression
discontinuity design and randomized natural or policy
experiments – offer internal validity almost as strong as
a randomized-controlled trial.
 Quasi-experiments have established the real-world
causal impacts of HIV testing and initiation of ART on
health and economic outcomes, as well as indirect
effects on other community members.
 Quasi-experiments have established the causal effects
of immediate versus deferred ART in real-world clinical
settings; and have evaluated specific interventions to
improve patient performance in the cascade of care.
 Quasi-experiments can be implemented where
randomized clinical trials are infeasible or unethical,
and should be integrated better into methods for
evidence synthesis.
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assignment – analogous to corrections for noncom-
pliance in randomized trials [11]. In rare but oppor-
tune quasi-experiments, treatment assignment is
actually randomized – just not by the investigator,
for example as in the Vietnam Draft Lottery [13,14]
andMendelian Randomization of genetic traits [15].
Common across all of these quasi-experimental
designs, the researcher identifies a source of exogen-
ous, quasi-random (or random) variation occurring
in the world and designs a study to analyze it. We
note that our definition differs from some others in
the literature, which define a quasi-experiment as a
prospective study in which the investigator assigns
treatment in a controlled environment, but does so
nonrandomly [16]. Under our definition, the ‘exper-
iment’ in the quasi-experiment arises not because
the investigator has intervened, but because treat-
ment was assigned – at least in part – by some
exogenous factors which can either be observed or
isolated by the researcher. Sometimes, researchers
are not able to measure a specific source of exogen-
ous variation (e.g. an instrument), but are never-
theless able to control for large sets of unobserved
confounders, for example through the use of fixed
effects [17]. These studies have been termed ‘weak
quasi-experiments’ [18
&&
].
STRENGTHS AND LIMITATIONS OF
QUASI-EXPERIMENTAL DESIGNS
The key strength of quasi-experimental designs vis-
a`-vis observational studies that rely on adjustment
formeasured covariates is the plausibility of assump-
tions required for valid causal inference. Although
there is substantial heterogeneity across quasi-
experimental designs, all seek to reduce reliance
on the assumption that there are no unobserved
confounders. Figure 1 provides a schematic ranking
of different study designs in order of their reliance
on the assumption of no unobserved confounding.
The ordering of study designs in Figure 1 is an
approximation: internal validity in quasi-exper-
iments will depend on the source of exogenous
variation and whether it can credibly be considered
as-good-as-random. For example, a bad instru-
mental variable will lead to inferences no better
than most regression analyses. Additionally, we
reflect in the figure that the boundaries between
design categories – experiment, quasi-experiment,
and nonexperiment – are blurry. Under some
definitions, truly randomized exposures are
considered experiments, even if the investigator is
not involved in treatment assignment. Similarly,
under some definitions, difference-in-differences
models are considered quasi-experiments even if
no specific source of exogenous variation is identi-
fied [18
&&
].
Quasi-experiments have several important
advantages over randomized-controlled trials. They
offer opportunities to study the effectiveness of
interventions implemented at scale in real-world
settings, and to study the effectiveness across differ-
ent populations and points in time. Quasi-exper-
iments can evaluate interventions that randomized
trials cannot ethically test. And they are typically
much cheaper and may be more politically feasible
to conduct than randomized trials. Quasi-exper-
iments can often be implemented using existing
data, and opportunities to use such designs are
expanding with the proliferation of ‘big data’.
The key challenge in quasi-experimental designs
vis-a`-vis randomized-controlled trials is that the
investigator does not control treatment assignment.
Therefore, the investigator cannot be 100% certain
that treatment assignment was actually random (or
quasi-random). Rather, the investigator posits the
random or quasi-random process that gave rise to
treatment assignment, and then gathers evidence –
both qualitative and quantitative – to support this
assumption. The quality of a quasi-experimental
study depends on the strength of evidence support-
ing this interpretation, which typically relies on the
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FIGURE 1. Likelihood that the assumption of no unobserved confounding is satisfied.
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rigor and transparency with which supporting
assumptions are reported and tested (where
possible).
Quasi-experimental designs offer opportunities
to learn about the causal impacts of HIV care and
treatment as implemented in real-world settings and
to evaluate interventions to improve the cascade of
HIV care. In the rest of the article, we review the
extant quasi-experimental literature on the HIV
cascade of care, elucidating key ways that quasi-
experiments can generate data that randomized
trials cannot.
QUASI-EXPERIMENTS TO EVALUATE THE
IMPACT OF HIV CARE AND TREATMENT
Real-world health impacts of programmes as
implemented
Quasi-experimental designs have the ability to
identify impacts of programmes, policies and inter-
ventions as implemented, at scale, in real-world
settings. Programmes face myriad challenges such
as poor provider training, drug stock outs, absentee-
ism and low motivation among patients – contex-
tual factors that efficacy trials attempt to control.
Critically, behavioral responses of providers and
patients may mitigate (or reinforce) direct health
effects. For example, the scale-up of ARTmay lead to
the (false) perception that HIV is less prevalent
because fewer people are dying [19] and thus to
lower rates of HIV testing and enrolment in care.
On the contrary, the scale-up of ART could reduce
fears about learning one’s status, leading to
increased HIV testing and enrolment in care. The
causal effect of ART scale-up on HIV testing (and
downstream outcomes) is thus an empirical ques-
tion that can only be answered using observational
methods. Wilson [20] evaluates the staged geo-
graphic scale-up of ART in Zambia and finds that
while scale-up of ART increased HIV testing among
women and older men, it did not increase testing
among working-age men, possibly because of low
ART uptake in this group.
Another strength of quasi-experiments is the
ability to quantify the magnitude of effects where
the direction of effect is already known. There are
many cases where equipoise cannot be demon-
strated (A is known to be better than B), and yet
the magnitude of benefits – and thus the extent to
which scarce resources should be allocated to this
intervention vis-a`-vis other life-saving interven-
tions – remains uncertain. Randomized controlled
trials (RCTs) cannot provide evidence in such cases,
because without equipoise a trial of intervention
effects would be considered unethical. Because in
quasi-experiments the investigator does not (typi-
cally) control treatment assignment, quasi-experi-
ments are considered ethical even if equipoise
cannot (or can no longer) be established. Good
examples in the HIV literature relate to the scale-
up of ART and health outcomes. Bendavid et al. [21]
use a difference-in-differences strategy to look at the
effect of PEPFAR funding on mortality, exploiting
the fact that which countries received PEPFAR fund-
ing was somewhat arbitrary. Bor et al. [22] use an
interrupted time series strategy with a modeled
counterfactual to assess the effect of ART scale-up
on population adult life expectancy in rural South
Africa, finding 11.3-year gains following the intro-
duction of mass treatment. Clearly, ART could not
be randomly assigned to some communities and not
others; and yet, causal evidence on the aggregate
population health impact of ART is important to
guide policy-making and resource allocation.
Quasi-experimental studies have also looked at
the health impacts of treatment for those patients
targeted. Bor et al. [10
&&
,23
&
] look at the causal effect
of early versus deferred ART eligibility on mortality
in a regression discontinuity design, finding large
gains in survivorship among patients with relatively
low CD4 counts (200 cells per microliter) but
who did not have other serious clinical symptoms
(Stage IV HIV illness). Exploiting the differential
scale-up of ART in Zambia, Lucas and Wilson [24]
identify increases in weight at the population level
among Zambian women likely to be HIV-positive.
Using sharp changes in temporal availability of ART
in the USA, Papageorge et al. [25] demonstrate
decreases in domestic violence and illicit drug use
among low-income, HIV-positive women.
Quasi-experimental study designs have also
been used to assess ART regimen choice. Nelson
et al. [26] use physician prescribing preference as
an instrument for whether a patient started a
proteinase-inhibitor or nonnucleoside reverse tran-
scriptase inhibitor-(NNRTI) based regimen, and find
substantially increased adherence among patients
started on an NNRTI. Several quasi-experimental
and experimental studies have evaluated the impact
of HIV testing on sexual behaviors and incidence of
sexually transmitted infections [27–30].
Spillover effects of interventions beyond the
health of patients in care
Cost–benefit calculations should capture the full
social costs and benefits of an intervention, includ-
ing nonhealth outcomes and spillover effects
beyond those persons directly targeted. Because of
financial and ethical constraints, however, rando-
mized trials are often stopped when the primary
Outcomes of ART in different populations
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health outcome is reached. Several difference-in-
differences studies have evaluated the economic
impacts of HIV treatment scale-up on patients’
productivity and labor supply, documenting
substantial though incomplete recovery [31–35].
Other studies have compared households where a
member initiated ART to those where no household
member initiated ART, and evaluated household
spillover effects on labor supply [31,36,37], time-
use [38], assets [33], health [36,39] and sexual behav-
iors [40].
Still other studies have exploited differential
changes in exposure to ART over space and time
to identify aggregate effects of ART scale-up on
economic outcomes [41,42] and sexual behavior
[43,44,45
&
] at the community level, and spillover
effects on the labor supply [19,46], education invest-
ments [47
&
] and sexual behaviors of HIV-uninfected
community members in particular [42]. For
example, Friedman [45
&
] exploits the differential
rollout of ART across regions of Kenya to measure
the effect of community ART availability on sexual
behavior and pregnancy in Kenya. In a recent study,
Wirth et al. [48] use an instrumental variables
approach to assess the impact of local area ART
coverage on HIV incidence, replicating quasi-exper-
imentally the results of an influential nonexperi-
mental study [49].
External validity across a range of settings
Effects may be context specific. One key strength of
quasi-experiments is the ability to replicate analyses
across settings even after a clinical benefit has been
established. As an example, the effects of ART on
labor market outcomes will depend on local labor
market conditions. Much faster recovery of labor
supply was observed in an agricultural setting in
western Kenya [31] and among employees of com-
panies in Kenya and Botswana [31–34] than in a
general patient population in rural South Africa
where work opportunities were scarce [35]. Quasi-
experiments can contribute to systematic knowl-
edge of how effects may vary across contexts.
In sum, these quasi-experimental studies have
demonstrated very large population health impacts
of ART scale-up [21,22,24], with substantial health
[10
&&
,23
&
] and economic [31–35] benefits accruing
to patients on ART. Further, the impacts of ART
extend beyond patients themselves and include
economic and health benefits to members of house-
holds [37,38,50,51] and the broader community
[19,23
&
,47
&
]. The threat of sexual disinhibition is
real [43,44,45
&
], but is very likely outweighed by
the reduction in transmission from persons on
ART [45
&
,49].
QUASI-EXPERIMENTS TO IMPROVE
PROGRESSION THROUGH THE CASCADE
OF HIV CARE
Although quasi-experiments have generated sub-
stantial evidence about the real-world clinical and
population impacts of HIV care and treatment,
fewer studies have evaluated the impacts of specific
interventions to improve patient progression
through the cascade of HIV care. Nevertheless, prog-
ress has been made and this is a growing literature.
Three studies used difference-in-differences
approaches to establish the impact of interventions
on HIV testing: DeWalque et al. [52
&
] find that using
‘pay-for-performance’ provider incentives modestly
increases HIV testing and counseling services in
Rwanda; Goetz et al. [53] found that provider edu-
cation and feedback improved rates of HIV testing in
Veterans Administration facilities; and McGovern
et al. [54] showed that a food voucher gift to the
heads of households in a community in rural Kwa-
Zulu-Natal, South Africa, increased consent to
home-based HIV testing among all householdmem-
bers. Klein et al. [55] used an interrupted time series
design to assess the rollout of routine HIV testing in
North Carolina and found close to zero impact on
case detection.
Once patients test positive, how can they best be
linked into long-run care and treatment? Bor et al.
[10
&&
,23
&
] assessed the causal impacts of immediate
versus deferred ART eligibility for patients present-
ing for care in rural South Africa, using a regression
discontinuity design. Patients presenting just above
the 200-cell CD4 count eligibility threshold had
higher mortality, lower retention in care and lower
CD4 counts at follow-up than patients presenting
with CD4 counts just below the threshold. Further
down the cascade, Boruett et al. [56] conducted a
controlled interrupted time series design to evaluate
a facility-level ART adherence intervention in
Kenya, and found small but significant improve-
ments in patient adherence.
CONCLUSION
Quasi-experimental methods have been used exten-
sively to evaluate the impact of HIV care and treat-
ment scale-up, although this literature is largely in
economics and is not widely cited in the main-
stream HIV literature. Recent quasi-experiments
have generated valuable evidence on specific inter-
ventions to improve progression across the HIV
treatment cascade, for example better understand-
ing the causal effect of offering patients immediate
access to ART rather than referring them to pre-ART
care, in real-world settings. Quasi-experiments have
Quasi-experiments to establish causal effects of HIV care Bor et al.
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also been used effectively in HIV research beyond
the ‘cascade of care’, for example to evaluate the
effect of interventions in preventing new HIV infec-
tions [57
&
,58] and reducing stigma [59], and in the
estimation of HIV prevalence in the context of
selective nonresponse [60,61
&
]. With the increasing
collection of large administrative, surveillance and
clinical datasets, and the ability to link these sour-
ces, the opportunities for rigorous quasi-exper-
iments will only grow.
Current guidelines for evidence synthesis (for
example the GRADE criteria used by WHO, http://
www.gradeworkinggroup.org) and for reporting of
studies (for example STROBE guidelines) do not
make separate recommendations for quasi-exper-
imental studies. Quasi-experiments are typically
graded as observational, nonexperimental studies,
but this assessment does not allow that some quasi-
experiments, for example regression discontinuity
designs and randomized natural or policy exper-
iments, yield inferences nearly as strong as random-
ized clinical trials. Furthermore, the features of a
rigorously-presented quasi-experimental study dif-
fer from the features of a rigorously-presented
cohort or casecontrol study.
Should there be a third GRADE category for
quasi-experiments? Devising checklists for the
assessment of quasi-experiments is difficult because
of the wide range of data-generating processes that
generate quasi-experiments, and the wide range of
methods used to analyze them. Often, specific sub-
ject area knowledge is required to determine the
plausibility of assumptions invoked in a quasi-
experiment. And yet, the potential of these designs
to produce rigorous, actionable evidence to improve
patient care, policy design and resource allocation is
too great to be ignored. Quasi-experimental studies
have been widely accepted in the social sciences as
valid methods of inquiry [4,5]. Quasi-experiments
are gaining increasing appreciation and use in
clinical and population health research [10
&&
,12,
62
&
]. Future research should focus on approaches
to better integrate quasi-experiments into methods
for evidence synthesis [18
&&
,63].
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